Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.

Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U.

J Alzheimers Dis. 2019 May 27. doi: 10.3233/JAD-190187. [Epub ahead of print]

PMID:
31156172
2.

CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.

Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldö M, Nilsson C, Blennow K, van Swieten JC, Janelidze S.

Ann Clin Transl Neurol. 2019 Mar 29;6(5):863-872. doi: 10.1002/acn3.763. eCollection 2019 May.

3.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30492-8. doi: 10.1016/j.clinbiochem.2019.05.005. [Epub ahead of print]

4.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30488-6. doi: 10.1016/j.clinbiochem.2019.05.006. [Epub ahead of print]

PMID:
31129181
5.

Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia.

Meeter LHH, Steketee RME, Salkovic D, Vos ME, Grossman M, McMillan CT, Irwin DJ, Boxer AL, Rojas JC, Olney NT, Karydas A, Miller BL, Pijnenburg YAL, Barkhof F, Sánchez-Valle R, Lladó A, Borrego-Ecija S, Diehl-Schmid J, Grimmer T, Goldhardt O, Santillo AF, Hansson O, Vestberg S, Borroni B, Padovani A, Galimberti D, Scarpini E, Rohrer JD, Woollacott IOC, Synofzik M, Wilke C, de Mendonca A, Vandenberghe R, Benussi L, Ghidoni R, Binetti G, Niessen WJ, Papma JM, Seelaar H, Jiskoot LC, de Jong FJ, Donker Kaat L, Del Campo M, Teunissen CE, Bron EE, Van den Berg E, Van Swieten JC.

J Neurol Neurosurg Psychiatry. 2019 May 23. pii: jnnp-2018-319784. doi: 10.1136/jnnp-2018-319784. [Epub ahead of print]

6.

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression.

Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E.

NPJ Parkinsons Dis. 2019 May 3;5:7. doi: 10.1038/s41531-019-0079-3. eCollection 2019.

7.

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.

Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0. Review.

8.

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.

Sjöström H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, Svenningsson P, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6079. doi: 10.1038/s41598-019-42565-4.

9.

18F-Flortaucipir in TDP-43 associated frontotemporal dementia.

Smith R, Santillo AF, Waldö ML, Strandberg O, Berron D, Vestberg S, van Westen D, van Swieten J, Honer M, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6082. doi: 10.1038/s41598-019-42625-9.

10.

CSF and blood biomarkers for Parkinson's disease.

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P.

Lancet Neurol. 2019 Jun;18(6):573-586. doi: 10.1016/S1474-4422(19)30024-9. Epub 2019 Apr 10. Review.

PMID:
30981640
11.

Corrigendum to: "Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms" [Psychiatry Research: Neuroimaging. Volume 275 (May 2018), Pages 5-13].

Owens-Walton C, Jakabek D, Li X, Wilkes FA, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Hansson O.

Psychiatry Res Neuroimaging. 2019 Apr 30;286:76. doi: 10.1016/j.pscychresns.2019.03.013. No abstract available.

PMID:
30955528
12.

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly.

Hahn A, Strandberg TO, Stomrud E, Nilsson M, van Westen D, Palmqvist S, Ossenkoppele R, Hansson O.

Cereb Cortex. 2019 Mar 16. pii: bhz020. doi: 10.1093/cercor/bhz020. [Epub ahead of print]

13.

Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?

Londos E, Hansson O, Rosén I, Englund E.

BMJ Case Rep. 2019 Mar 9;12(3). pii: e228177. doi: 10.1136/bcr-2018-228177.

PMID:
30852516
14.

Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling.

Lampinen B, Szczepankiewicz F, Novén M, van Westen D, Hansson O, Englund E, Mårtensson J, Westin CF, Nilsson M.

Hum Brain Mapp. 2019 Jun 1;40(8):2529-2545. doi: 10.1002/hbm.24542. Epub 2019 Feb 25.

15.

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.

Zettergren A, Höglund K, Kern S, Thorvaldsson V, Johan Skoog M, Hansson O, Andreasen N, Bogdanovic N, Blennow K, Skoog I, Zetterberg H.

Sci Rep. 2019 Feb 21;9(1):2460. doi: 10.1038/s41598-018-36650-3.

16.

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.

Håkansson C, Torisson G, Londos E, Hansson O, van Westen D.

Neuroradiology. 2019 Apr;61(4):397-404. doi: 10.1007/s00234-019-02156-6. Epub 2019 Jan 17.

17.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease.

Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O.

Alzheimers Dement. 2019 Apr;15(4):570-580. doi: 10.1016/j.jalz.2018.12.001. Epub 2019 Jan 25.

PMID:
30639421
18.

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.

Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, Palmqvist S, Hansson O.

Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9.

19.

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study.

Voevodskaya O, Poulakis K, Sundgren P, van Westen D, Palmqvist S, Wahlund LO, Stomrud E, Hansson O, Westman E; Swedish BioFINDER Study Group.

Neurology. 2019 Jan 4. pii: 10.1212/WNL.0000000000006852. doi: 10.1212/WNL.0000000000006852. [Epub ahead of print]

20.

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.

Cicognola C, Brinkmalm G, Wahlgren J, Portelius E, Gobom J, Cullen NC, Hansson O, Parnetti L, Constantinescu R, Wildsmith K, Chen HH, Beach TG, Lashley T, Zetterberg H, Blennow K, Höglund K.

Acta Neuropathol. 2019 Feb;137(2):279-296. doi: 10.1007/s00401-018-1948-2. Epub 2018 Dec 13.

21.

Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma.

Nilholm C, Roth B, Höglund P, Blennow K, Englund E, Hansson O, Zetterberg H, Ohlsson B.

Nutr Res. 2018 Dec;60:13-25. doi: 10.1016/j.nutres.2018.08.002. Epub 2018 Aug 19.

PMID:
30527256
22.

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.

Smith R, Wibom M, Pawlik D, Englund E, Hansson O.

JAMA Neurol. 2018 Dec 3. doi: 10.1001/jamaneurol.2018.3692. [Epub ahead of print]

23.

Genetic characterization of amyloid-β and tau network spread.

Ossenkoppele R, Hansson O.

Nat Med. 2018 Dec;24(12):1790-1792. doi: 10.1038/s41591-018-0277-2. No abstract available.

PMID:
30510252
24.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2018 Nov 20. doi: 10.1093/ije/dyy230. [Epub ahead of print]

25.

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.

Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study.

Hum Brain Mapp. 2019 Feb 1;40(2):638-651. doi: 10.1002/hbm.24401. Epub 2018 Oct 19.

PMID:
30368979
26.

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms.

Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER study, Mattsson N, Hansson O.

Alzheimers Dement. 2019 Feb;15(2):194-204. doi: 10.1016/j.jalz.2018.08.014. Epub 2018 Oct 23.

27.

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.

JAMA. 2018 Sep 18;320(11):1151-1162. doi: 10.1001/jama.2018.12917.

28.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.

Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA, Groot C, van Berckel BNM, van der Flier WM, Scheltens P, Rohrer JD, Warren JD, Schott JM, Fox NC, Sanchez-Valle R, Grau-Rivera O, Gelpi E, Seelaar H, Papma JM, van Swieten JC, Hodges JR, Leyton CE, Piguet O, Rogalski EJ, Mesulam MM, Koric L, Nora K, Pariente J, Dickerson B, Mackenzie IR, Hsiung GR, Belliard S, Irwin DJ, Wolk DA, Grossman M, Jones M, Harris J, Mann D, Snowden JS, Chrem-Mendez P, Calandri IL, Amengual AA, Miguet-Alfonsi C, Magnin E, Magnani G, Santangelo R, Deramecourt V, Pasquier F, Mattsson N, Nilsson C, Hansson O, Keith J, Masellis M, Black SE, Matías-Guiu JA, Cabrera-Martin MN, Paquet C, Dumurgier J, Teichmann M, Sarazin M, Bottlaender M, Dubois B, Rowe CC, Villemagne VL, Vandenberghe R, Granadillo E, Teng E, Mendez M, Meyer PT, Frings L, Lleó A, Blesa R, Fortea J, Seo SW, Diehl-Schmid J, Grimmer T, Frederiksen KS, Sánchez-Juan P, Chételat G, Jansen W, Bouchard RW, Laforce RJ, Visser PJ, Ossenkoppele R.

Ann Neurol. 2018 Nov;84(5):729-740. doi: 10.1002/ana.25333.

29.

Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.

Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):165-170. doi: 10.1136/jnnp-2018-318956. Epub 2018 Sep 25.

PMID:
30254084
30.

Turning Vice into Virtue: Using Batch-Effects to Detect Errors in Large Genomic Data Sets.

Mafessoni F, Prasad RB, Groop L, Hansson O, Prüfer K.

Genome Biol Evol. 2018 Oct 1;10(10):2697-2708. doi: 10.1093/gbe/evy199.

31.

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.

Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O.

Sci Rep. 2018 Sep 5;8(1):13276. doi: 10.1038/s41598-018-31517-z.

32.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.

Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.

Neurobiol Aging. 2018 Nov;71:81-90. doi: 10.1016/j.neurobiolaging.2018.07.003. Epub 2018 Jul 11.

PMID:
30107289
33.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study.

Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, Palmqvist S, Stomrud E, Hansson O.

Alzheimers Res Ther. 2018 Aug 7;10(1):77. doi: 10.1186/s13195-018-0403-x.

34.

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.

Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M.

J Cereb Blood Flow Metab. 2018 Aug 3:271678X18791430. doi: 10.1177/0271678X18791430. [Epub ahead of print]

PMID:
30073880
35.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O.

Neurology. 2018 Aug 28;91(9):e867-e877. doi: 10.1212/WNL.0000000000006082. Epub 2018 Jul 27.

36.

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.

Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2018 Sep 1;141(9):2755-2771. doi: 10.1093/brain/awy189.

37.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review.

Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, Molinuevo JL, Shaw LM, Vandijck M, Verbeek MM, Savage M, Mattsson N, Lewczuk P, Batrla R, Rutz S, Dean RA, Blennow K.

Alzheimers Dement. 2018 Oct;14(10):1313-1333. doi: 10.1016/j.jalz.2018.05.008. Epub 2018 Jun 23. Review.

PMID:
29940161
38.

Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes.

Gusarova V, O'Dushlaine C, Teslovich TM, Benotti PN, Mirshahi T, Gottesman O, Van Hout CV, Murray MF, Mahajan A, Nielsen JB, Fritsche L, Wulff AB, Gudbjartsson DF, Sjögren M, Emdin CA, Scott RA, Lee WJ, Small A, Kwee LC, Dwivedi OP, Prasad RB, Bruse S, Lopez AE, Penn J, Marcketta A, Leader JB, Still CD, Kirchner HL, Mirshahi UL, Wardeh AH, Hartle CM, Habegger L, Fetterolf SN, Tusie-Luna T, Morris AP, Holm H, Steinthorsdottir V, Sulem P, Thorsteinsdottir U, Rotter JI, Chuang LM, Damrauer S, Birtwell D, Brummett CM, Khera AV, Natarajan P, Orho-Melander M, Flannick J, Lotta LA, Willer CJ, Holmen OL, Ritchie MD, Ledbetter DH, Murphy AJ, Borecki IB, Reid JG, Overton JD, Hansson O, Groop L, Shah SH, Kraus WE, Rader DJ, Chen YI, Hveem K, Wareham NJ, Kathiresan S, Melander O, Stefansson K, Nordestgaard BG, Tybjærg-Hansen A, Abecasis GR, Altshuler D, Florez JC, Boehnke M, McCarthy MI, Yancopoulos GD, Carey DJ, Shuldiner AR, Baras A, Dewey FE, Gromada J.

Nat Commun. 2018 Jun 13;9(1):2252. doi: 10.1038/s41467-018-04611-z.

39.

The clinical significance of 10-m walk test standardizations in Parkinson's disease.

Lindholm B, Nilsson MH, Hansson O, Hagell P.

J Neurol. 2018 Aug;265(8):1829-1835. doi: 10.1007/s00415-018-8921-9. Epub 2018 Jun 6.

40.

Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?

Hansson O, Mormino EC.

Brain. 2018 May 1;141(5):1241-1244. doi: 10.1093/brain/awy065. No abstract available.

PMID:
29701788
41.

Amyloid blood biomarker detects Alzheimer's disease.

Nabers A, Perna L, Lange J, Mons U, Schartner J, Güldenhaupt J, Saum KU, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H.

EMBO Mol Med. 2018 May;10(5). pii: e8763. doi: 10.15252/emmm.201708763.

42.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
43.

Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms.

Owens-Walton C, Jakabek D, Li X, Wilkes FA, Walterfang M, Velakoulis D, van Westen D, Looi JCL, Hansson O.

Psychiatry Res Neuroimaging. 2018 May 30;275:5-13. doi: 10.1016/j.pscychresns.2018.03.004. Epub 2018 Mar 7. Erratum in: Psychiatry Res Neuroimaging. 2019 Apr 30;286:76.

PMID:
29555381
44.

18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.

Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.

Sci Rep. 2018 Mar 16;8(1):4717. doi: 10.1038/s41598-018-23041-x.

45.

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.

Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P, Wessman Y, Shaat N, Spégel P, Mulder H, Lindholm E, Melander O, Hansson O, Malmqvist U, Lernmark Å, Lahti K, Forsén T, Tuomi T, Rosengren AH, Groop L.

Lancet Diabetes Endocrinol. 2018 May;6(5):361-369. doi: 10.1016/S2213-8587(18)30051-2. Epub 2018 Mar 5.

PMID:
29503172
46.

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Nov;14(11):1470-1481. doi: 10.1016/j.jalz.2018.01.010. Epub 2018 Mar 1.

47.

N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism.

Ström K, Morales-Alamo D, Ottosson F, Edlund A, Hjort L, Jörgensen SW, Almgren P, Zhou Y, Martin-Rincon M, Ekman C, Pérez-López A, Ekström O, Perez-Suarez I, Mattiasson M, de Pablos-Velasco P, Oskolkov N, Ahlqvist E, Wierup N, Eliasson L, Vaag A, Groop L, Stenkula KG, Fernandez C, Calbet JAL, Holmberg HC, Hansson O.

Sci Rep. 2018 Feb 14;8(1):3016. doi: 10.1038/s41598-018-21099-1.

48.

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.

Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, Grøntvedt GR, Bråthen G, Begcevic I, Moussaud S, Minthon L, Hansson O, Diamandis EP, White LR, Nielsen HM.

Alzheimers Res Ther. 2018 Jan 29;10(1):9. doi: 10.1186/s13195-018-0336-4.

49.

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review.

Ygland E, van Westen D, Englund E, Rademakers R, Wszolek ZK, Nilsson K, Nilsson C, Landqvist Waldö M, Alafuzoff I, Hansson O, Gustafson L, Puschmann A.

Alzheimers Res Ther. 2018 Jan 9;10(1):2. doi: 10.1186/s13195-017-0330-2.

50.

Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study.

Surova Y, Nilsson M, Lampinen B, Lätt J, Hall S, Widner H, van Westen D, Hansson O.

Neuroradiology. 2018 Mar;60(3):247-254. doi: 10.1007/s00234-017-1971-3. Epub 2018 Jan 24.

Supplemental Content

Loading ...
Support Center